Trial Profile
Implementation of HIV pre-exposure prophylaxis with antiretroviral medications amongst men at high risk for HIV infection; a demonstration project to evaluate feasibility, acceptability and adherence
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms QPrEP
- 08 Oct 2019 Status changed from active, no longer recruiting to discontinued.
- 18 Oct 2018 Status changed from completed to active, no longer recruiting.
- 18 Oct 2018 Planned number of patients changed from 300 to 3000.